Efficacy and Safety Analysis of Immune Checkpoint Inhibitors plus Angiogenesis Inhibitors for the Treatment of Advanced Driver-negative NSCLC in Elderly Patients: A Retrospective Study

Background and Objective: Immune checkpoint inhibitors (ICIs) combined with angiogenesis inhibitors may have synergistic effects in elderly patients with advanced driver-negative NSCLC, but its true efficacy remains unclear. In addition, chemotherapy tolerance in elderly NSCLC patients is poor, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian, Zou, Zhonghua, Tan, Jie, Shi, Jianping, Yang, Hui, Wang, Hao, Zhou, Jundong, Xue, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266243/
https://www.ncbi.nlm.nih.gov/pubmed/37325057
http://dx.doi.org/10.7150/jca.83719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266243/
https://www.ncbi.nlm.nih.gov/pubmed/37325057
http://dx.doi.org/10.7150/jca.83719

Ejemplares similares